samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Horizon Discovery Partners with Sophia Genetics on NGS Reference Standards for Oncology Applications

Horizon Discovery Group

Global leader in data-driven medicine and leader in the application of gene editing technologies announce their new partnership

  • Partnership combines Horizon’s HDx™ Reference Standards with Sophia Genetics’ artificial intelligence
  • The use of Horizon’s Reference Standards will improve the quality of molecular profiling by SOPHiA™ artificial intelligence in oncology patient samples
  • Users of the Sophia DDM® analytical platform will immediately benefit from the partnership to closely monitor the performance of their genomic tests
LAUSANNE, Switzerland and Cambridge, UK – 17 November 2016: Sophia Genetics, the global leader in Data-Driven Medicine, and Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world-leader in the application of gene editing technologies, today announced they have entered into a new partnership to improve the quality of Next Generation Sequencing (NGS) based genetic testing in oncology patient samples.

Under the terms of the agreement, Horizon’s HDx™ Reference Standards will be combined with Sophia Genetics’ artificial intelligence, providing hospitals and laboratories with more accurate and high quality NGS testing services, assays and genomic data analysis.

In particular, current and future users of the Sophia DDM® analytical platform will be able to assess the quality of their NGS assays, reaching the highest levels of sensitivity and specificity. The use of HDx Reference Standards will help with performance monitoring as well as reproducibility and repeatability of NGS tests.

Jurgi Camblong, Chief Executive Officer and co-founder, Sophia Genetics, commented:“The quality of molecular profiling is a cornerstone of NGS testing and relies on a series of technical steps being performed correctly, from the collection of patient samples and DNA extraction, to creating and analysing genomic data. Sophia Genetics helps hospitals and laboratories to make the most of their NGS testing and we are delighted to combine Horizon’s Reference Standards with our artificial intelligence for Data-Driven Medicine, increasing the number of patients that will benefit from reliable NGS genomic testing results.”

Dr. Darrin M. Disley, Chief Executive Officer, Horizon Discovery Group, commented:“Our new partnership with Sophia Genetics demonstrates the increasingly important role well validated controls have in the provision of molecular assays, especially for complex technologies such as NGS as they become more widely adopted. We look forward to working closely with Sophia Genetics as our Reference Standards become an important component of their workflows.”

Financial terms for the partnership have not been disclosed.
phone +44 (0)1223 655 580
web www.horizondiscovery.com/
email 7100 Cambridge Research Park, Waterbeach, Cambridge, CB25 9TL
 
Print this page
Send to a friend
   
spacer
News and Press Releases

World-leading cancer stem cell expert joins Avacta Scientific Advisory Board

Developer of biotherapeutics and research reagents announces the appointment of Professor Gerard Evan to its Scientific Advisory Board
More info >>


White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

Industry Events

Highly Potent Active Pharmaceutical Ingredients 2017

22-23 May 2017, Copthrone Tara Hotel, Scarsdale Place, Kensington, London, UK

The global market for Highly Potent Active Pharmaceutical Ingredients is currently on a growth fast track, largely driven by its major use in oncology for cancer treatment and more often in the form of ADCs.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement